As a patent attorney, Fabian Koenigbauer has helped clients secure, expand and enforce patent rights in both the U.S. and globally for more than 15 years. He specializes in building patent portfolios for small and large molecules (biologics), analyzing freedom-to-operate issues, maximizing patent term and developing patent protection for products subject to Hatch-Waxman or biologics litigations. He also advises his clients on adverse patent matters, including litigation, oppositions and AIA trials, and participates in AIA trials on the sides of both patent challengers and patent owners.
He has prepared and prosecuted patent applications for biologics in clinical trials on behalf of one the world largest pharmaceutical companies. He has assisted clients with various Hatch-Waxman-related strategies, including obtaining patent protection for drugs subject to 505(b)(2) applications, preparing the underlying assertions for a paragraph IV certification for an ANaDA, opinions of counsel directed to patents involved in ANDA litigations and assessing the scope of innovator patents.
In addition, he practices aspects of domestic and international patent law, with a specific focus on the life sciences industry. His educational background in biochemistry and biotechnology, as well as his professional experience working with clients at all stages of product development, including products in pre-clinical trials and clinical trials, enables him to help clients develop their patent portfolios, assert their patent rights and defend against infringement allegations.
Fabian also routinely provides strategic counsel to clients on the processes of intellectual property transactions, including due diligences, portfolio development, licensing and litigation, with particular experience in developing and managing global patent portfolios in the life sciences industry. He has also represented clients in post-grant proceedings in the USPTO, including post-grant reviews. In addition, Fabian has asserted and defended patents through pre-litigation investigations, discovery, trials and appeals in the Federal Circuit. He has advised clients ranging from small companies and start-ups to Fortune 100 companies.
Strategic portfolio management
- Manages patent portfolios for Fortune 50 pharmaceutical company regarding cancer treatment, stem cell and related technologies, working on behalf of client through domestic and foreign patent prosecution at various stages of the technologies’ clinical development.
Adversarial Patent Matters
- Assisted with strategies relating to discovery for foreign adverse proceedings under 28 U.S.C. § 1782.
Deals and product developments
- Assists a consumer health care subunit of a major pharmaceutical company with potential legal issues surrounding product developments, including freedom to operate and patent landscaping.